We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Researchers Identify Genes Linked to the Development of Monogenic Diabetes

By LabMedica International staff writers
Posted on 02 Mar 2020
By studying a well controlled group of young Lithuanian diabetes patients, researchers were able to identify genes linked to the development of the rare monogenic form of diabetes.

Monogenic diabetes, which results from a mutation in one of the genes involved in the regulation of blood sugar levels, represents approximately one to 4% of all cases of the disease. More...
Monogenic diabetes is frequently confused with type I or type II diabetes, and more than 90% of monogenic cases are misdiagnosed.

To correct this situation, investigators at the Université de Genève (Switzerland) and the Lithuanian University of Health Sciences (Vilnius) took advantage of the fact that Lithuania has a register of all diabetic children, which also includes most of the young adults. For the current study, the investigators assessed 1209 pediatric and young adult diabetic patients for diabetes-related autoimmune antibodies. They then screened all antibody-negative patients using targeted high-throughput sequencing of more than 300 potential candidate genes.

Results revealed that in the group of 153 patients lacking autoimmune antibodies, 40.7% had monogenic diabetes, with the highest percentage (100%) in infants (diagnosis at ages 0–12 months), followed by those diagnosed at ages from one to 18 years (40.3%) and at 18 to 25 years (22.2%).

The overall prevalence of monogenic diabetes in diabetic youth in Lithuania was 3.5% (1.9% for glucokinase diabetes, 0.7% for hepatocyte nuclear factor 1 homeobox A, 0.2% for hepatocyte nuclear factor 4 alpha and ATP binding cassette subfamily C member 8, 0.3% for potassium inwardly rectifying channel subfamily J member 11, and 0.1% for insulin). Likely pathogenic variants were also detected in 11 additional genes.

"Hyperglycemia should therefore be considered as a symptom of various diseases, rather than a disease in itself, and different forms of diabetes should be better screened," said senior author Dr. Valérie Schwitzgebel, professor of pediatrics, gynaecology, and obstetrics at Université de Genève. "The earlier the actual cause is identified, the sooner appropriate treatments can be initiated, minimizing the risk for long term complications."

The monogenic diabetes paper was published in the February 21, 2020, online edition of the journal Diabetes.

Related Links:
Université de Genève
Lithuanian University of Health Sciences



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.